据周日报道，Whitehawk Therapeutics在AACN 2026上展示了HWK-007、HWK-016和HWK-206下一代ADC产品组合的临床前数据，显示低单位毫克毫克/公斤剂量下的肿瘤消退

2026-04-20 16:29

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform
Tumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC)
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026